Pneumocystis jiroveci Pneumonia in Adult Patients with AIDS
暂无分享,去创建一个
[1] F. Ognibene,et al. The Laboratory Evaluation of Opportunistic Pulmonary Infections , 1996, Annals of Internal Medicine.
[2] C. Beard,et al. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. , 2000, The Journal of infectious diseases.
[3] S. T. Pottratz,et al. Gamma‐interferon inhibits Pneumocystis carinii attachment to lung cells by decreasing expression of lung cell‐surface integrins , 1997, European journal of clinical investigation.
[4] C. Jaspers,et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy , 1999, The Lancet.
[5] A. Telenti,et al. The New England Jour nal of Medicine DISCONTINUATION OF PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN HIV-1–INFECTED ADULTS TREATED WITH COMBINATION ANTIRETROVIRAL THERAPY , 2022 .
[6] C. Beard,et al. Update on the epidemiology and transmission of Pneumocystis carinii. , 2002, Microbes and infection.
[7] S. Oka,et al. (1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia , 1996, Clinical and diagnostic laboratory immunology.
[8] W. Martin,et al. Pneumocystis carinii attachment to cultured lung cells by pneumocystis gp 120, a fibronectin binding protein. , 1991, The Journal of clinical investigation.
[9] A. Moorman,et al. Discontinuation of Chemoprophylaxis against Pneumocystis carinii Pneumonia in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[10] R. Baughman,et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031. , 1994, The Journal of infectious diseases.
[11] J. Borleffs,et al. Efficacy and Toxicity of Two Doses of Trimethoprim-Sulfamethoxazole as Primary Prophylaxis against Pneumocystis carinii Pneumonia in Patients with Human Immunodeficiency Virus , 1995 .
[12] R. Garland,et al. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. , 1998, Chest.
[13] H. Masur,et al. The interaction in vitro of Pneumocystis carinii with macrophages and L- cells , 1978, The Journal of experimental medicine.
[14] R. Miller,et al. Detection of Pneumocystis carinii with DNA amplification , 1990, The Lancet.
[15] R. Baughman,et al. Increased Pneumocystis carinii recovery from the upper lobes in Pneumocystis pneumonia. The effect of aerosol pentamidine prophylaxis. , 1993, Chest.
[16] J. Hopkin,et al. A search for Pneumocystis carinii in post‐mortem lungs by DNA amplification , 1992, The Journal of pathology.
[17] J. Beck,et al. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[18] J. Nielsen,et al. Antibody response to a major humanPneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia , 1993, European Journal of Clinical Microbiology and Infectious Diseases.
[19] J. D. Marshall,et al. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. , 1990, The American journal of pathology.
[20] R. Rose,et al. Surfactant protein-A reduces binding and phagocytosis of pneumocystis carinii by human alveolar macrophages in vitro. , 1998, American journal of respiratory cell and molecular biology.
[21] H. Waskin,et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. , 1992, The New England journal of medicine.
[22] N. Markowitz,et al. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired immune deficiency syndrome. , 1995, American journal of respiratory and critical care medicine.
[23] A. Fishman,et al. Alveolar response to experimental Pneumocystis carinii pneumonia in the rat. , 1980, The American journal of pathology.
[24] S. Meshnick,et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. , 2000, The Journal of infectious diseases.
[25] A. Roth,et al. Light and electron microscopy study of carbohydrate antigens found in the electron-lucent layer of Pneumocystis carinii cysts , 1997, Parasitology Research.
[26] D. Stover,et al. The use of a simple exercise test for the diagnosis of Pneumocystis carinii pneumonia in patients with AIDS. , 1989, The American review of respiratory disease.
[27] P. Hopewell,et al. Lack of effect of prophylactic aerosolized pentamidine on the detection of Pneumocystis carinii in induced sputum or bronchoalveolar lavage specimens. , 1993, Archives of pathology & laboratory medicine.
[28] C. Bernard,et al. Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus-infected patients during one or several episodes of pneumonia , 1997, Journal of clinical microbiology.
[29] C. Haidaris,et al. Pneumocystis carinii is not universally transmissible between mammalian species , 1993, Infection and immunity.
[30] D. Finkelstein,et al. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] R. Hirschtick,et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. , 1995, The New England journal of medicine.
[32] G. Berry,et al. Pneumocystis carinii Pneumonia: CT and HRCT Observations , 1990, Journal of computer assisted tomography.
[33] D. Armstrong,et al. Pneumocystis carinii pneumonia: a cluster of eleven cases. , 1975, Annals of internal medicine.
[34] J. Edman,et al. Gene for an extracellular matrix receptor protein from Pneumocystis carinii. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[35] D. Santi,et al. Isolation and expression of the Pneumocystis carinii thymidylate synthase gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Nielsen,et al. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. , 1992, Journal of Infectious Diseases.
[37] K. Kawakami,et al. Analysis of Cellular Response and Gamma Interferon Synthesis in Bronchoalveolar Lavage Fluid and Lung Homogenate of Mice Infected with Pneumocystis carinii , 1995, Microbiology and immunology.
[38] P. Walzer,et al. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. , 1995, The Journal of clinical investigation.
[39] M. Lasbury,et al. Down-Regulation of GATA-2 Transcription duringPneumocystis carinii Infection , 2000, Infection and Immunity.
[40] P. Avilés,et al. Activities of Sordarins in Experimental Models of Candidiasis, Aspergillosis, and Pneumocystosis , 2000, Antimicrobial Agents and Chemotherapy.
[41] J. McCutchan,et al. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial , 1999, The Lancet.
[42] A. Mocroft,et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy , 2001 .
[43] B. Dong,et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] G. Maguire,et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. , 1987, Chest.
[45] W. El-Sadr,et al. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] S. Yale,et al. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. , 1996, Mayo Clinic proceedings.
[47] J. Kovacs,et al. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[48] B. Garvy,et al. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses , 1997, Infection and immunity.
[49] J. Rehg,et al. Experimental Pneumocystis carinii pneumonia in the ferret. , 1987, British journal of experimental pathology.
[50] W. Hughes. Pneumocystis carinii pneumonia , 2010 .
[51] S. Merali,et al. S-adenosylmethionine concentrations in diagnosis of Pneumocystis carinii pneumonia , 2003, The Lancet.
[52] J. Finkelstein,et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. , 1999, The Journal of clinical investigation.
[53] W. El-Sadr,et al. Correlation of bronchoalveolar lavage cell populations with clinical severity of Pneumocystis carinii pneumonia. , 1988, Chest.
[54] P. Walzer,et al. Nude mouse: a new experimental model for Pneumocystis carinii infection. , 1977, Science.
[55] J. Mills,et al. Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia. , 1991, Journal of acquired immune deficiency syndromes.
[56] V. Soriano,et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy , 2000, AIDS.
[57] J. Curtis,et al. The usefulness of induced sputum in the diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. , 2015, The American review of respiratory disease.
[58] M. Moore,et al. Susceptibility to Pneumocystis carinii in mice is dependent on simultaneous deletion of IFN-gamma and type 1 and 2 TNF receptor genes. , 1998, Journal of immunology.
[59] S. Meshnick,et al. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. , 1998, The Journal of infectious diseases.
[60] M. Goetz,et al. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. , 1992, Archives of internal medicine.
[61] M. B. Taylor,et al. The neutrophil chemiluminescence response to Pneumocystis carinii is stimulated by GM-CSF and gamma interferon. , 1991, FEMS microbiology immunology.
[62] P. Hopewell,et al. Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome , 1988, Antimicrobial Agents and Chemotherapy.
[63] D. Perl,et al. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostic, and clinical features. , 1976, National Cancer Institute monograph.
[64] L. La Voie,et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. , 1990, The New England journal of medicine.
[65] J. Mills,et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.
[66] J. Kovacs,et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. , 1999, The Journal of infectious diseases.
[67] Dennis Schmatz,et al. Efficacy of MK-991 (L-743,872), a Semisynthetic Pneumocandin, in Murine Models ofPneumocystis carinii , 1998, Antimicrobial Agents and Chemotherapy.
[68] J. Shellito,et al. IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. , 1999, Journal of immunology.
[69] J. Finkelstein,et al. Analysis of cytokine mRNA profiles in the lungs of Pneumocystis carinii-infected mice. , 1997, American journal of respiratory cell and molecular biology.
[70] Q. Eichbaum,et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. , 1998, The Journal of clinical investigation.
[71] E. Dei‐Cas,et al. In Vitro Pharmacodynamic Parameters of Sordarin Derivatives in Comparison with Those of Marketed Compounds against Pneumocystis carinii Isolated from Rats , 2000, Antimicrobial Agents and Chemotherapy.
[72] W. Webb,et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. , 1997, AJR. American journal of roentgenology.
[73] J. Stringer,et al. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. , 1989, Experimental parasitology.
[74] Stephanie Schrag,et al. Prevention of Perinatal Group B Streptococcal Disease Revised Guidelines from CDC , 2002 .
[75] S. Meshnick,et al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. , 1997, The Journal of infectious diseases.
[76] J. Curtis,et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. , 1991, American journal of respiratory cell and molecular biology.
[77] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[78] J. Shellito,et al. Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. , 1995, American journal of respiratory and critical care medicine.
[79] A. Limper,et al. Modulation of Pneumocystis carinii adherence to cultured lung cells by a mannose-dependent mechanism. , 1991, The Journal of laboratory and clinical medicine.
[80] Smith Js,et al. Attachment of Pneumocystis carinii to rat pneumocytes. , 1986 .
[81] S. Spector,et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. , 1995, The New England journal of medicine.
[82] D. Bartley,et al. A natural source of infection due to pneumocystis carinii. , 1983, The Journal of infectious diseases.
[83] P. Meier,et al. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. , 1990, The New England journal of medicine.
[84] J. Golden,et al. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial. , 1990, Annals of internal medicine.
[85] A. Harmsen,et al. Resolution of Pneumocystis carinii pneumonia in CD4+ lymphocyte- depleted mice given aerosols of heat-treated Escherichia coli , 1992, The Journal of experimental medicine.
[86] C. Cunningham-Rundles,et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. , 1981, The New England journal of medicine.
[87] A. Limper,et al. Alveolar macrophage interactions with Pneumocystis carinii. , 1999, The Journal of laboratory and clinical medicine.
[88] K. Yoneda,et al. Attachment of Pneumocystis carinii to Type I Alveolar Cells Studied by Freeze-Fracture Electron Microscopy , 1983, Infection and immunity.
[89] P. Hopewell,et al. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. , 1986, Annals of internal medicine.
[90] B. Bender,et al. Current issues in the use of theophylline. , 1993, The American review of respiratory disease.
[91] A. Wakefield. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora , 1996, Journal of clinical microbiology.
[92] R. Rose,et al. Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro. , 2000, American journal of respiratory cell and molecular biology.
[93] J. Montaner,et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients , 2001, AIDS.
[94] S. Follansbee,et al. Oral Atovaquone Compared with Intravenous Pentamidine for Pneumocystis carinii Pneumonia in Patients with AIDS , 1994, Annals of Internal Medicine.
[95] M. Moroni,et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. , 2000, The Journal of infectious diseases.
[96] W. G. Campbell,et al. Pneumocystis carinii in lungs of rats treated with cortisone acetate. Ultrastructural observations relating to the life cycle. , 1969, The American journal of pathology.
[97] K. McIntyre,et al. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii , 1992, The Journal of experimental medicine.
[98] P. Goodman,et al. Pulmonary cysts associated with Pneumocystis carinii pneumonia in patients with AIDS. , 1989, Radiology.
[100] M. Fischl,et al. Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocystis carinii Pneumonia in AIDS , 1988 .
[101] E. Israel,et al. Diagnostic yield of bronchoalveolar lavage and bronchoscopic lung biopsy for detection of Pneumocystis carinii. , 1996, Mayo Clinic proceedings.
[102] D. Schmatz,et al. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[103] J. Hendley,et al. Activation and Transmission in Rats of Infection with Pneumocystis 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[104] N. Obel,et al. Phagocytosis and stimulation of the respiratory burst in neutrophils by Pneumocystis carinii. , 1993, The Journal of infectious diseases.
[105] C. Beard,et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. , 2001, The Journal of infectious diseases.
[106] N. Benowitz,et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. , 1990, The New England journal of medicine.
[107] K. Yoneda,et al. Interaction of Pneumocystis carinii with host lungs: an ultrastructural study. , 1980, Infection and immunity.
[108] Wangxue Chen,et al. Latency is not an inevitable outcome of infection with Pneumocystis carinii , 1993, Infection and immunity.
[109] P. Dickman,et al. Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. , 1989, The American review of respiratory disease.
[110] J. Shellito,et al. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. , 1990, The Journal of clinical investigation.
[111] D. Stover,et al. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis carinii pneumonia. , 1990, Annals of internal medicine.
[112] M. Sogin,et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the Fungi , 1988, Nature.
[113] E. A. Havell,et al. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against Pneumocystis carinii infection , 1992, Infection and immunity.
[114] R. Mccabe,et al. Atypical presentations of Pneumocystis carinii pneumonia in patients receiving inhaled pentamidine prophylaxis. , 1990, Chest.
[115] W. T. Hughes. Pneumocystis carinii pneumonitis. , 1987, The New England journal of medicine.
[116] J. Standing,et al. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells , 1993, Infection and immunity.
[117] G A Noskin,et al. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[118] Y. van der Graaf,et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. , 1992, The New England journal of medicine.
[119] K. Bartizal,et al. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies , 1996, Infection and immunity.
[120] A. Baggish,et al. Antiparasitic Agent Atovaquone , 2002, Antimicrobial Agents and Chemotherapy.
[121] A. Limper,et al. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. , 1990, The Journal of clinical investigation.
[122] J. Genner,et al. Pneumocystis carinii in human lungs at autopsy. , 1986, Scandinavian journal of infectious diseases.
[123] J. Stringer,et al. Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci , 1997, Journal of clinical microbiology.
[124] M. Cushion,et al. Techniques for examining Pneumocystis carinii in fresh specimens , 1986, Journal of clinical microbiology.
[125] A. Wakefield. Detection of DNA sequences identical to Pneumocystis carinii in samples of ambient air. , 1994, The Journal of eukaryotic microbiology.
[126] A. Telenti,et al. Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study , 2001, AIDS.
[127] B. Garvy,et al. Role of gamma interferon in the host immune and inflammatory responses to Pneumocystis carinii infection , 1997, Infection and immunity.
[128] K. Heyrman,et al. An outbreak of Pneumocystis carinii pneumonia at a pediatric hospital. , 1978, Pediatrics.
[129] J. Stringer,et al. Cellular and molecular biology of Pneumocystis carinii. , 1991, International review of cytology.
[130] D. Williams,et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor , 1991, Nature.
[131] J E Parrillo,et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. , 1988, The New England journal of medicine.
[132] E. Pesanti. Interaction of cytokines and alveolar cells with Pneumocystis carinii in vitro. , 1991, The Journal of infectious diseases.
[133] Richard D Moore,et al. Community-acquired pneumonia: impact of immune status. , 1995 .
[134] A. Harmsen,et al. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice , 1990, The Journal of experimental medicine.
[135] M. J. Almela,et al. Antifungal Activities and Cytotoxicity Studies of Six New Azasordarins , 2001, Antimicrobial Agents and Chemotherapy.
[136] Mary E. Wilson,et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations , 1995 .
[137] M. B. Taylor,et al. Opsonophagocytosis of Pneumocystis carinii. , 1992, Journal of medical microbiology.
[138] J. Shellito,et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. , 1997, American journal of respiratory cell and molecular biology.
[139] Frenkel Jk,et al. Latent Pneumocystis infection of rats, relapse, and chemotherapy. , 1966 .
[140] H. Marcotte,et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. , 1996, The Journal of infectious diseases.
[141] Z. Mohsenifar,et al. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS. A randomized trial. , 1990, Annals of internal medicine.
[142] W. Craig,et al. Pneumocystis carinii induction of tumor necrosis factor-alpha by alveolar macrophages: modulation by pentamidine isethionate. , 1992, Immunology letters.
[143] D. Stover,et al. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. , 1984, Annals of internal medicine.
[144] K. Yoneda,et al. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia , 1980, Infection and immunity.
[145] J. Falloon,et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. , 1993, The New England journal of medicine.
[146] E. Tamburrini,et al. Biodiversity of Pneumocystis carinii hominis: typing with different DNA regions , 1997, Journal of clinical microbiology.
[147] H. Masur,et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. , 1981, The New England journal of medicine.
[148] C. Giffen,et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis Carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. , 2001, The Journal of infectious diseases.
[149] V. Kelly,et al. Sordarins: A New Class of Antifungals with Selective Inhibition of the Protein Synthesis Elongation Cycle in Yeasts , 1998, Antimicrobial Agents and Chemotherapy.
[150] P. Walzer,et al. Characterization of Rat CD4 T Cell Clones Specific for the Major Surface Glycoprotein of Pneumocystis carinii , 1997, The Journal of eukaryotic microbiology.
[151] K. Holmes,et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[152] J. Phair,et al. Serologic responses to Pneumocystis carinii antigens in health and disease. , 1990, The Journal of infectious diseases.
[153] D. Richman,et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1990, The New England journal of medicine.
[154] P. Walzer,et al. Cellular responses to a 55-kilodalton recombinant Pneumocystis carinii antigen , 1994, Infection and immunity.
[155] M. Shaw,et al. Lipid transfer from human epithelial cells to Pneumocystis carinii in vitro. , 1997, The Journal of infectious diseases.
[156] J. Whitsett,et al. Granulocyte-Macrophage Colony-Stimulating Factor in the Innate Immune Response to Pneumocystis carinii Pneumonia in Mice1 , 2000, The Journal of Immunology.
[157] C. Beard,et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study , 2001, The Lancet.
[158] J. Shelhamer,et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. , 1987, The New England journal of medicine.
[159] P. Kvale,et al. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. , 1997, American journal of respiratory and critical care medicine.
[160] J. Miro,et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. , 1993, AIDS.
[161] C. Beard,et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. , 2004, The Journal of infectious diseases.
[162] F. Ognibene,et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. , 1989, Annals of internal medicine.
[163] R. Helmke,et al. Pneumocystis carinii induces an oxidative burst in alveolar macrophages , 1992, Infection and immunity.
[164] E. Pesanti,et al. Uptake and degradation of Pneumocystis carinii by macrophages in vitro. , 2015, The American review of respiratory disease.
[165] J. Ioannidis,et al. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. , 1996, Archives of internal medicine.
[166] M. Ypma-Wong,et al. Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii , 1992, Infection and immunity.
[167] A. Wakefield,et al. Mitochondrial gene sequences show fungal homology for Pneumocystis carinii , 1991, Molecular microbiology.
[168] Albert Wu,et al. Comparison of Three Regimens for Treatment of Mild to Moderate Pneumocystis carinii Pneumonia in Patients with AIDS: A Double-Blind, Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine , 1996, Annals of Internal Medicine.
[169] A. Mocroft,et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.
[170] V. Baselski,et al. Rapid detection of Pneumocystis carinii in bronchoalveolar lavage samples by using Cellufluor staining , 1990, Journal of clinical microbiology.
[171] J. Lundgren,et al. Update on Pneumocystis carinii f. sp.hominis Typing Based on Nucleotide Sequence Variations in Internal Transcribed Spacer Regions of rRNA Genes , 1998, Journal of Clinical Microbiology.
[172] E. A. Havell,et al. Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response , 1993, Infection and immunity.
[173] W. El-Sadr,et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. , 1998, The New England journal of medicine.
[174] J. Montaner,et al. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) , 1990, Annals of internal medicine.
[175] J. Ruskin,et al. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. , 1988, Annals of internal medicine.
[176] D. Schmatz,et al. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat , 1995, Antimicrobial agents and chemotherapy.
[177] Baozheng Li,et al. Prevalence of Various Pneumocystis carinii sp. f. hominis Types in Different Geographical Locations , 1996, The Journal of eukaryotic microbiology.
[178] J. Shelhamer,et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. , 1984, Annals of internal medicine.
[179] R. Smith,et al. Elevated lactate dehydrogenase values in patients with Pneumocystis carinii pneumonia. , 1988, Chest.
[180] H. Masur. Prevention and treatment of pneumocystis pneumonia. , 1992, The New England journal of medicine.
[181] D. L. Coleman,et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. , 1986, Annals of internal medicine.
[182] P. Hopewell. Pneumocystis carinii pneumonia: diagnosis. , 1988, The Journal of infectious diseases.
[183] G. Sakaguchi,et al. Intestinal Absorption of Botulinum Toxins of Different Molecular Sizes in Rats , 1977, Infection and immunity.
[184] S. Weiss. Tissue destruction by neutrophils. , 1989, The New England journal of medicine.
[185] W. Oyen,et al. Pro‐inflammatory cytokines in lung and blood during steroid‐induced Pneumocystis carinii pneumonia in rats , 1996, Journal of leukocyte biology.
[186] Henrik Nielsen,et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? , 1999, AIDS.
[187] W. Hughes. Natural mode of acquisition for de novo infection with Pneumocystis carinii. , 1982, The Journal of infectious diseases.
[188] J. Ose,et al. A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis against Pneumocystis carinii Pneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection , 2001 .
[189] L. Klobutcher,et al. Differential DNA amplification and copy number control in the hypotrichous ciliate Euplotes crassus. , 1991, The Journal of protozoology.
[190] J. Lundgren,et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia , 1999, The Lancet.
[191] W. Hughes. Prevention and treatment of Pneumocystis carinii pneumonia. , 1991, Annual review of medicine.
[192] J. Standing,et al. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. , 1997, The Journal of clinical investigation.
[193] A. Heryet,et al. Observations favouring Pneumocystis carinii pneumonia as a primary infection: a monoclonal antibody study on paraffin sections , 1988, The Journal of pathology.
[194] H. D. Liggitt,et al. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon , 1991, Infection and immunity.
[195] J. Phair,et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. , 1990, The New England journal of medicine.
[196] M. Leibowitz,et al. Typing of Pneumocystis carinii strains that infect humans based on nucleotide sequence variations of internal transcribed spacers of rRNA genes , 1994, Journal of clinical microbiology.
[197] J. Domínguez,et al. Identification of Elongation Factor 2 as the Essential Protein Targeted by Sordarins in Candida albicans , 1998, Antimicrobial Agents and Chemotherapy.
[198] M. Lindegren,et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[199] G. Wormser,et al. Trimethoprim‐sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial , 1992, AIDS.
[200] R. Speich,et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. , 1994, Journal of acquired immune deficiency syndromes.
[201] M. Shaw,et al. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo , 1996, Antimicrobial agents and chemotherapy.
[202] I. Fraser,et al. Pneumocystis carinii enhances soluble mannose receptor production by macrophages. , 2000, Microbes and infection.
[203] Jeffrey L. Jones,et al. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[204] D. Chin,et al. Effect of aerosolized pentamidine prophylaxis on the clinical severity and diagnosis of Pneumocystis carinii pneumonia. , 1992, The American review of respiratory disease.
[205] S. Meshnick,et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. , 2001, JAMA.
[206] B. Palmer,et al. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. , 1996, The Journal of laboratory and clinical medicine.
[207] J. Smith,et al. Typing of Pneumocystis carinii strains with type-specific oligonucleotide probes derived from nucleotide sequences of internal transcribed spacers of rRNA genes , 1995, Journal of clinical microbiology.
[208] M. Dumont,et al. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[209] R. Garland,et al. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. , 2000, Chest.